While genome editing is widely accepted as a promising therapy for hereditary disorders, its potential in treating high‐risk infectious diseases (e.g., AIDS) by disrupting key host factors (e.g., C–C chemokine receptor type 5, CCR5) has only started to be explored recently.33 The gene discussed is CCR5; the disease is infectious disease.